Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms

Biologicals

Volumn 35, Issue 4, 2007, Pages 329-334

  Burnouf, Thierry ^a   Terpstra, Fokke ^b   Habib, George ^c   Seddik, Salwa ^c  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b CENTRAL LABORATORY   (Netherlands)

^c Egyptian Org Biol Prod/Vacc P   (Egypt)

Author keywords

Acid pH; Antivenom; Caprylate; Horse; Immunoglobulins; Plasma; Safety; Virus

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; LIPID; OCTANOIC ACID; PEPSIN A; VENOM ANTISERUM;

ANIMAL CELL; ARTICLE; BOVINE DIARRHEA VIRUS; CLEARANCE; DIGESTION; DILUTION; DRUG CONTAMINATION; DRUG MANUFACTURE; FLAVIVIRUS; FRACTIONATION; NONHUMAN; PH; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; VESICULAR STOMATITIS VIRUS; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS INFECTIVITY;

ANIMALS; ANTIVENINS; CATTLE; CELL LINE; CERCOPITHECUS AETHIOPS; DIARRHEA VIRUS 1, BOVINE VIRAL; DRUG CONTAMINATION; EGYPT; ENCEPHALOMYOCARDITIS VIRUS; HERPESVIRUS 1, SUID; HORSES; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; OCTANOIC ACIDS; PEPSIN A; VERO CELLS; VESICULOVIRUS; VIRUS INACTIVATION; ZOONOSES;

ANIMALIA; BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1; ENCEPHALOMYOCARDITIS VIRUS; EQUIDAE; SUID HERPESVIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 35348898600     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.11.003     Document Type: Article

References (33)

1. Theakston R.D., Warrell D.A., and Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 41 (2003) 541-557
2. Chippaux J.P., and Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 36 (1998) 823-846
3. CPMP. Note for guidance on production and quality control of animal immunoglobulins and immunsera for human use (2002-2002), European Agency for the Evaluation of Medicinal Products (EMEA), London. http://www.emea.eu.int p.1-14
4. Grandgeorge M., Véron J.L., Lutsch C., Makula M.F., Riffard P., Pépin S., et al. Preparation of improved F(ab′)2 antivenoms. An example: new polyvalent European viper antivenom (equine). In: Bon C., and Goyffon M. (Eds). Envenomings and their treatments (1996), Fondation Marcel Mérieux, Lyon 161-172
5. Denton A. Practical experience with the use of Planova 15N in the manufacture of FDA approved products (November 2004), Asahi kasei, Lisbon, Portugal p.8-9
6. Burnouf T., Radosevich M., Goubran H.A., and Willkommen H. Place of nanofiltration for assuring viral safety of biologicals. Curr Nanosci 1 (2005) 189-201
7. Chippaux J.P. Snake-bites: appraisal of the global situation. Bull World Health Organ 76 (1998) 515-524
8. Gutierrez J.M., Theakston R.D., and Warrell D.A. Confronting the neglected problem of snake bite envenoming: The need for a global partnership. PLoS Med 3 (2006) e150
9. Burnouf T., Griffiths E., Padilla A., Seddik S., Stephano M.A., and Gutierrez J.M. Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals 32 (2004) 115-128
10. CPMP. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (revised) (1996-1996), European Agency for the Evaluation of Medicinal Products (EMEA), London. http://www.emea.eu.int CPMP/BWP/CPMP/5136/03
11. Anonymous. German Federal requirements "Requirements of validation studies for demonstrating the virus safety of medicinal products derived from human blood plasma". 1994.
12. WHO. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products (2003), WHO, Geneva. www.who.int p.1-72
13. Seddik S.S., Wanas S., Shehata A., Fawaz S., and Helmy M.H. Development of an improved method for production of antiscorpion F(ab′)2 fragment of IgG with high yield and potency. J Nat Toxins 11 (2002) 123-132
14. Pope C. The action of proteolytic enzymes on the antitoxins and proteins in immune sera. I. True digestion of the proteins. Br J Exp Pathol 20 (1939) 132
15. Grechushkina-Sukhorukova V.A., Telbukh V.P., and Stepepanov V.M. Proteolysis of horse blood serum proteins at various stages of antitoxic sera production by the Diaferm-3-Method. Prikl Biokhim Mikrobiol 20 (1984) 528-533
16. Steinbuch M., and Audran R. Isolation of IgG immunoglobulin from human plasma using caprylic acid. Rev Fr Etud Clin Biol 14 (1969) 1054-1058
17. dos Santos M.C., D'Imperio Lima M.R., Furtado G.C., Colletto G.M., Kipnis T.L., and Dias da Silva W. Purification of F(ab′)2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. Toxicon 27 (1989) 297-303
18. Rojas G., Jimenez J.M., and Gutierrez J.M. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 32 (1994) 351-363
19. Terpstra F.G., Kleijn M., Koenderman A.H., Over J., van Engelenburg F.A., Schuitemaker H., et al. Viral safety of C1-inhibitor NF. Biologicals (2006)
20. Terpstra F.G., Parkkinen J., Tolo H., Koenderman A.H., Ter Hart H.G., von Bonsdorff L., et al. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 90 (2006) 21-32
21. Bos O.J., Sunye D.G., Nieuweboer C.E., van Engelenburg F.A., Schuitemaker H., and Over J. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. Biologicals 26 (1998) 267-276
22. Reid K.G., Cuthbertson B., Jones A.D., and McIntosh R.V. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products. Vox Sang 55 (1988) 75-80
23. Yap P.L. The viral safety of intravenous immune globulin. Clin Exp Immunol 104 Suppl. 1 (1996) 35-42
24. Burnouf T., and Radosevich M. Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Rev 14 (2000) 94-110
25. Omar A., Kempf C., Immelmann A., Rentsch M., and Morgenthaler J.J. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation. Transfusion 36 (1996) 866-872
26. Hamalainen E., Suomela H., and Ukkonen P. Virus inactivation during intravenous immunoglobulin production. Vox Sang 63 (1992) 6-11
27. Burnouf-Radosevich M. Viral safety of intravenous immunoglobulins G for therapeutic use. Transfus Clin Biol 2 (1995) 167-179 [in French]
28. Dichtelmuller H., Rudnick D., and Kloft M. Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution. Biologicals 30 (2002) 135-142
29. Korneyeva M., Hotta J., Lebing W., Rosenthal R.S., Franks L., and Petteway Jr. S.R. Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 30 (2002) 153-162
30. Parkkinen J., Rahola A., von Bonsdorff L., Tolo H., and Torma E. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sang 90 (2006) 97-104
31. Goubran H.A., Burnouf T., and Radosevich M. Virucidal heat-treatment of single plasma units: a potential approach for developing countries. Haemophilia 6 (2000) 597-604
32. Gutiérrez J.M., Higashi H.G., Wen F.H., and Burnouf T. Strengthening antivenom production in Central and South American public laboratories: Report of a workshop. Toxicon 49 (2007) 30-35
33. WHO. Supply of life saving antisera: a growing need for concern. WHO Drug Information 20 (2006) 5-6